Combination Moderate-Intensity Statin and Ezetimibe Therapy for Elderly Patients With Atherosclerosis

Area of Science:

• Cardiology
• Pharmacology
• Geriatrics

Background:

• High-intensity statins pose a higher risk of intolerance and adverse events in elderly patients.
• Careful consideration is needed for routine high-intensity statin use in older individuals.

Purpose of the Study:

• To evaluate moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in elderly patients with atherosclerotic cardiovascular disease (ASCVD).
• To compare the efficacy and safety of these lipid-lowering strategies in different age groups.

Main Methods:

• Post hoc analysis of the RACING (RAndomized Comparison of Efficacy and Safety of Lipid-lowerING With Statin Monotherapy Versus Statin/Ezetimibe Combination for High-risk Cardiovascular Diseases) trial.
• Patients stratified by age (≥75 years and <75 years).
• Primary endpoint: 3-year composite of cardiovascular death, major cardiovascular events, or nonfatal stroke.

Main Results:

• No significant difference in the primary endpoint between moderate-intensity statin with ezetimibe and high-intensity statin monotherapy in patients aged ≥75 years (10.6% vs 12.3%) and <75 years (8.8% vs 9.4%).
• Moderate-intensity statin with ezetimibe demonstrated significantly lower rates of intolerance-related drug discontinuation or dose reduction in both elderly (2.3% vs 7.2%) and younger (<75 years) patient groups.

Conclusions:

• Moderate-intensity statin with ezetimibe provides comparable cardiovascular benefits to high-intensity statin monotherapy in elderly ASCVD patients.
• The combination therapy is associated with improved tolerability, reducing discontinuation and dose adjustments, particularly beneficial for older adults at higher risk of intolerance.